Full-Time
Posted on 11/1/2025
Prescription price comparison and coupons
$81k - $173k/yr
California, USA
In Person
GoodRx provides price comparisons, coupons, and discounts for prescription medications through its website and mobile app. It partners with pharmacies to offer savings at the point of sale, earning referral fees. It also offers GoodRx Gold subscription with deeper discounts and earns revenue from ads and partnerships. The goal is to save people money on prescriptions and improve access to affordable medicines.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Santa Monica, California
Founded
2005
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, and vision insurance
401(k) with a company match
ESPP
Unlimited vacation
"Take care of yourself" days
11 paid holidays
Doceree appoints former GoodRx executive Andrew Matthews as senior VP, patient affordability. Today Doceree announced the appointment of Andrew Matthews, formerly VP, business development at GoodRx, as senior VP patient affordability. In this role, Matthews will lead strategic growth and commercialization initiatives for co-pay.com - Doceree's affordability platform purpose-built to activate co-pay benefits at the point of prescribing. The appointment reflects Doceree's accelerating investment in patient affordability as a core strategic pillar. Unlike consumer-facing affordability platforms, co-pay.com operates within physician engagement environments - closing the gap between co-pay program awareness and actual patient benefit activation. Matthews' experience scaling digital affordability programs at one of the country's most recognized prescription savings platforms positions him to lead this next phase of growth with measurable clinical and commercial impact. "Affordability and access are defining priorities in healthcare marketing today," said Harshit Jain, MD, Founder & Global CEO, Doceree. "co-pay.com is built on a fundamentally different premise - we activate benefits where the prescribing decision happens, not after the fact. Andrew's background at GoodRx, where he worked at the frontier of digital affordability and pharma partnerships, gives us exactly the right leadership to scale this platform and demonstrate measurable access outcomes for our life sciences partners." Kamya Elawadhi, Co-founder and President, Doceree, added, "Andrew brings a rare combination of platform-scaling experience and deep expertise in pharma affordability partnerships. Having built and expanded affordability programs at GoodRx that reached millions of patients, he understands both the scale that is possible and the gaps that remain. co-pay.com is designed to fill those gaps - and Andrew is the right leader to bring that story to market." At GoodRx, Matthews served as Vice President, Business Development, where he helped expand the company's pharma manufacturer partnerships and digital affordability initiatives aimed at reducing prescription cost barriers for patients at scale. His experience spans both the consumer and manufacturer sides of the affordability equation - a dual perspective he now brings to co-pay.com's continued expansion. "What sets Doceree apart is where and how affordability is activated," said Matthews. "co-pay.com does not wait for a patient to find a coupon on their own - it brings the benefit to them at the moment a physician is making a prescribing decision. That is a fundamentally more effective model. Having spent years working on the consumer side of affordability at GoodRx, I have seen firsthand where the journey gaps are. This platform is built to solve exactly that. I am excited to help scale it." Thomas Shea, Chief Revenue Officer-Patient Affordability & AI, Doceree, added, "Andrew's track record of building commercial affordability programs at scale, combined with his deep knowledge of the pharma manufacturer landscape, will directly accelerate co-pay.com's reach and strengthen the measurable value we deliver to life sciences brands and their patients." Matthews' appointment is the latest in a series of senior leadership additions as Doceree continues to expand its AI-powered operating system for healthcare marketing - integrating affordability, programmatic media, physician engagement intelligence, and AI-driven solutions across the full patient care journey. In his role, he will report directly to Thomas Shea, Chief Revenue Officer, Doceree.
GoodRx reported full-year 2025 revenue of $796.9 million, up 1%, and adjusted EBITDA of $270.5 million. However, the company guided 2026 revenue to $750–780 million and adjusted EBITDA of at least $230 million, signalling near-term pressure as it invests in growth initiatives. The company is pivoting towards its rebranded GoodRx Pharma Direct business, which grew approximately 41% in 2025 to $151.4 million. The division now includes roughly 200 manufacturer partnerships and over 100 brand self-pay programmes, with management expecting at least 30% growth in 2026. GoodRx is expanding its retail footprint, tripling its e-commerce presence and raising order volume 83% quarter-over-quarter. The company secured direct contracts with nine of the top ten retail pharmacies and launched employer and condition-based subscriptions, including weight loss offerings.
GoodRx reported fourth-quarter revenue of $194.8 million, beating analyst estimates of $193.2 million despite a 1.9% year-on-year decline. The company's adjusted earnings per share of $0.09 met expectations. However, the stock dropped 11.8% following disappointing forward guidance. GoodRx's full-year revenue guidance of $765 million came in 6.2% below analyst estimates, whilst EBITDA guidance of $230 million fell short of the $282.1 million expected. The healthcare technology company's customer base declined to 5.3 million from 5.4 million in the previous quarter. Over the past two years, GoodRx's customer base has averaged 9.5% year-on-year declines, though revenue per customer has increased. The company's market capitalisation stands at $804.5 million.
GoodRx expands into employer market with launch of 'goodrx employer direct' [business wire].
GoodRx has launched GoodRx Employer Direct, enabling employers to subsidise high-cost brand medications, including GLP-1 weight loss drugs, by applying targeted subsidies to discounted cash prices from pharmaceutical manufacturers. The offering is designed to complement traditional health plans without adding complexity. The platform allows employers to select medications like Wegovy and subsidise manufacturer-sponsored prices available through GoodRx, with contributions automatically applied at pharmacy counters. Midwestern grocery chain Hy-Vee is among the first employer partners using the service, which launched earlier this year. Employer Direct also offers customised telemedicine solutions integrating clinical care, prescribing and pharmacy fulfilment. The service leverages GoodRx's pharmaceutical partnerships and nationwide pharmacy network to provide transparent pricing whilst maintaining existing health plan structures.